@article{9c12a206d9854772ba0aa6e8e898e978,
title = "Call for action: expanding global access to hereditary cancer genetic testing",
author = "Brittany Bychkovsky and Rana, \{Huma Q.\} and Foluso Ademuyiwa and Jennifer Plichta and Karen Anderson and Ang{\'e}lica Nogueira-Rodrigues and Santa-Maria, \{Cesar A.\} and Coffman, \{Lan G.\} and Carol Marquez and Arunangshu Das and Alphonse Taghian and Koeller, \{Diane R.\} and Sandoval, \{Renata L.\} and Park, \{Ben Ho\} and Dizon, \{Don S.\}",
note = "Funding Information: DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. JP reports funding from the Color Foundation unrelated to this work. CAS-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received Sozo bioimpedance equipment for an investigator-led study on lymphoedema. AN-R reports honoraria and support for attending meetings and travel from Roche, MSD, Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors declare no competing interests. ",
year = "2022",
month = sep,
doi = "10.1016/S1470-2045(22)00378-3",
language = "English",
volume = "23",
pages = "1124--1126",
journal = "The Lancet Oncology",
issn = "1470-2045",
number = "9",
}